Anglonordic Life Science Conference 2022
As one of the organisers, Optimum is proud to partner with Anglonordic year on year to curate an awesome agenda for this fantastic event. Exclusively for European investors and R&D companies…
Tag Archive for: Optimum
Novo Holdings Portfolio Company ReViral to be Acquired by Pfizer
Deal value of up to US$525 million Novo Holdings co-led ReViral Series B financing in 2018 ReViral developing novel antiviral therapies to treat RSV infections Validation of Novo Holdings’ strategy to identify and invest in high quality European biotech opportunities Copenhagen, Denmark – Novo Holdings A/S, a leading international life sciences investor, today announces that its […]
eTheRNA Announces Relocation and Expansion of R&D Facility
GENT, BELGIUM, April 5, 2022 – eTheRNA immunotherapies NV (“eTheRNA”), an mRNA technology discovery and development company with a full platform of integrated capabilities, is pleased to announce the relocation of its R&D group to a new and larger site in Gent, Belgium. The upgraded R&D facility is in the Zwijnaarde Science Park, where a […]
Bionical Emas: Ian Fraser appointed as Executive Vice President, Clinical Development.
Bionical Emas, a global Contract Research Organisation (CRO) providing services to the pharmaceutical and biotech sectors, has appointed Ian Fraser as Executive Vice President (EVP) Clinical Development. Ian will be leading the Clinical Development team across the global business and becomes part of the Senior Leadership Team, reporting to COO, Tom Watson. Read more
Precirix raises EUR 80m in Series B to advance its pipeline of precision radiopharmaceuticals
Precirix NV, a clinical-stage biotechnology company developing precision radiopharmaceuticals in oncology, today announces the closing of a EUR 80m Series B financing round led by new investors INKEF Capital, Jeito Capital and Forbion as co-leads. Read more
